AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 165 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,828,281 | -13.4% | 154,678 | -0.9% | 0.00% | -50.0% |
| Q2 2023 | $4,418,939 | +53165.9% | 156,036 | -56.8% | 0.00% | -33.3% |
| Q1 2023 | $8,296 | -20.3% | 361,192 | -2.6% | 0.00% | -25.0% |
| Q4 2022 | $10,411 | -99.9% | 370,728 | +25.4% | 0.00% | +33.3% |
| Q3 2022 | $8,361,000 | +5.4% | 295,654 | -17.4% | 0.00% | 0.0% |
| Q2 2022 | $7,936,000 | -34.9% | 357,976 | -16.2% | 0.00% | -25.0% |
| Q1 2022 | $12,193,000 | -5.5% | 427,383 | +8.9% | 0.00% | 0.0% |
| Q4 2021 | $12,904,000 | -34.7% | 392,548 | -8.3% | 0.00% | -33.3% |
| Q3 2021 | $19,765,000 | -33.5% | 428,290 | -20.6% | 0.01% | -33.3% |
| Q2 2021 | $29,731,000 | +50.0% | 539,482 | +40.6% | 0.01% | +50.0% |
| Q1 2021 | $19,819,000 | +11.9% | 383,786 | -6.1% | 0.01% | 0.0% |
| Q4 2020 | $17,709,000 | +35.6% | 408,698 | +9.5% | 0.01% | +20.0% |
| Q3 2020 | $13,057,000 | -41.4% | 373,074 | -10.4% | 0.01% | -44.4% |
| Q2 2020 | $22,273,000 | +50.1% | 416,483 | -0.4% | 0.01% | +28.6% |
| Q1 2020 | $14,842,000 | -10.6% | 418,345 | +20.3% | 0.01% | +16.7% |
| Q4 2019 | $16,606,000 | +114.2% | 347,762 | +45.3% | 0.01% | +100.0% |
| Q3 2019 | $7,754,000 | -31.1% | 239,293 | +6.0% | 0.00% | -25.0% |
| Q2 2019 | $11,256,000 | +2201.8% | 225,664 | +2539.3% | 0.00% | +33.3% |
| Q4 2017 | $489,000 | -22.4% | 8,550 | -30.2% | 0.00% | -25.0% |
| Q2 2017 | $630,000 | -11.9% | 12,250 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $715,000 | +37.2% | 12,250 | -1.8% | 0.00% | +33.3% |
| Q4 2016 | $521,000 | -19.5% | 12,475 | +1.8% | 0.00% | -25.0% |
| Q3 2016 | $647,000 | +26.1% | 12,250 | 0.0% | 0.00% | +33.3% |
| Q2 2016 | $513,000 | -29.1% | 12,250 | -31.3% | 0.00% | -25.0% |
| Q1 2016 | $724,000 | +10.7% | 17,829 | +77.1% | 0.00% | +33.3% |
| Q4 2015 | $654,000 | -8.0% | 10,068 | 0.0% | 0.00% | -25.0% |
| Q3 2015 | $711,000 | -36.5% | 10,068 | 0.0% | 0.00% | -33.3% |
| Q2 2015 | $1,119,000 | +6.6% | 10,068 | -9.6% | 0.01% | 0.0% |
| Q1 2015 | $1,050,000 | -15.8% | 11,134 | 0.0% | 0.01% | -14.3% |
| Q4 2014 | $1,247,000 | – | 11,134 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |